Funding Support and Author Disclosures Dr Wiviott has received research grants to Brigham and Women’s Hospital from Amgen, AstraZeneca, Janssen, Merck, and Pfizer; has received consulting fees from Icon Clinical and Novo Nordisk; and his spouse is a former employee of Merck and current employee of Flagship Labs. Dr Berg has received research grant support to his institution from AstraZeneca and Pfizer; has received consulting fees from AstraZeneca, Mobility Bio, Inc, and Youngene Therapeutics; has received honoraria from the Medical Education Speakers Network (MESN) and USV Private Limited; and participates on clinical endpoint committees for studies sponsored by Kowa Pharmaceuticals. Drs Berg and Wiviott are members of the TIMI (Thrombolysis In Myocardial Infarction) Study Group, which has also received institutional research grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc, Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc, Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc, Roche, Siemens Healthcare Diagnostics, Inc, Softcell Medical Limited, The Medicines Company, and Zora Biosciences.